RESEARCH PAPER
Postpartum adiponectin changes in women with gestational diabetes
 
More details
Hide details
1
Chair and Department of Endocrinology, Medical University of Lublin
2
Department of Laboratory Diagnostics, Medical University of Lublin
3
Institute of Rural Health in Lublin
4
3rd Chair and Department of Gynecology, Medical University of Lublin
CORRESPONDING AUTHOR
Beata Matyjaszek-Matuszek   

Chair and Department of Endocrinology, Medical University of Lublin
 
Ann Agric Environ Med. 2014;21(4):850–853
KEYWORDS
ABSTRACT
introduction and objective:
Current literature provides contradictory information on the role of adiponectin (AdipoQ) in the course of gestational diabetes mellitus (GDM) and the changes after delivery. The aim of the study was to measure AdipoQ concentration in blood of women with GDM, and to conduct a comparative analysis of AdipoQ concentrations in gestation at 3 and 12 months after delivery.

Material and Methods:
The study group consisted of 50 women diagnosed with GDM between 24 and 28 weeks of gestation. Three months after delivery, 41 women underwent further tests, while 12 months after delivery 30 patients. All patients underwent clinical and laboratory evaluation at GDM diagnosis at 3 and 12 months after delivery. Laboratory evaluation included fasting glucose, fasting insulin, OGTT and lipid parameters in serum. Serum AdipoQ concentration was measured at GDM diagnosis as well as at 3 and 12 months after delivery.

Results:
AdipoQ concentrations did not differ significantly between the groups during gestation (p=0.7054) and 3 months after delivery (p=0.9732), while a significant rise was observed 12 months after delivery, compared to the values during pregnancy (p=0.0006). AdipoQ in the GDM group 12 months after delivery inversely correlated with fasting glucose and 2-hour post-load plasma glucose after a 75-g oral glucose tolerance test (r=-0.37 * ; p<0.05 and r=-0.42, p<0.05, respectively).

Conclusions:
An increased level of AdipoQ after delivery in the comparison to women with GDM may be a marker for reversibility of carbohydrate metabolism disorders, while a negative correlation between AdipoQ and glucose levels suggests that this parameter may be a predictor In the future of disturbances in glucose tolerance in women with GDM.

 
REFERENCES (29)
1.
Zalecenia kliniczne dotyczące postępowania u chorych na cukrzycę. Polskie Towarzystwo Diabetologiczne. Diabetol Prakt. 2011; 12: 39–41 (in Polish).
 
2.
Disse E, Graeppi-Dulac J, Joncour-Mills G, Dupuis O, Thivolet C. Heterogeneity of pregnancy outcomes and risk of LGA neonates in Caucasian females according to IADPSG criteria for gestational diabetes mellitus. Diabetes Metab. 2013; 39(2):132–138.
 
3.
Hunt KJ, Logan SL, Conway DL, Korte JE. Postpartum screening following GDM: how well are we doing? Curr Diab Rep. 2010; 10(3): 235–241.
 
4.
Verma A, Boney CM, Tucker R, Vohr BR. Insulin resistance syndrome in women with prior history of gestational diabetes mellitus. J Clin Endocrinol Metab. 2002; 87(7): 3227–3235.
 
5.
Sullivan SD, Umans JG, Ratner R. Gestational diabetes: implications for cardiovascular health. Curr Diab Rep. 2012; 12(1): 43–52.
 
6.
Heitritter SM, Solomon CG, Mitchell GF, Skali-Ounis N, Seely EW. Subclinical inflammation and vascular dysfunction in women with previous gestational diabetes mellitus. J Clin Endocrinol Metab. 2005; 90(7): 3983–3988.
 
7.
Antuna-Puente B, Feve B, Fellahi S, Bastard JP. Adipokines: the missing link between insulin resistance and obesity. Diabetes Metab. 2008; 34(1): 2–11.
 
8.
Gil-Campos M, Cañete RR, Gil A. Adiponectin, the missing link in insulin resistance and obesity. Clin Nutr. 2004; 23(5): 963–974.
 
9.
Karpe F. Insulin resistance by adiponectin deficiency: is the action in skeletal muscle? Diabetes. 2013; 62(3): 701–702.
 
10.
Mazaki-Tovi S, Kanety H, Sivan E. Adiponectin and human pregnancy. Curr Diab Rep. 2005; 5(4): 278–281.
 
11.
Retnakaran R, Hanley AJ, Raif N, Connelly PW, Sermer M, Zinman B. Reduced adiponectin concentration in women with gestational diabetes: a potential factor in progression to type 2 diabetes. Diabetes Care. 2004; 27(3): 799–800.
 
12.
Thyfault JP, Hedberg EM, Anchan RM, Thorne OP, Isler CM, Newton ER et al. Gestational diabetes is associated with depressed adiponectin levels. J Soc Gynecol Investig. 2005; 12(1): 41–45.
 
13.
Matyjaszek-Matuszek B, Lenart-Lipińska M, Kowalczyk-Bołtuć J, Szlichtyng W, Paszkowski T. Correlation between atherogenic risk and adiponectin in gestational diabetes mellitus. Ann Agric Environ Med. 2014; 21(1): 143–147.
 
14.
Dobiasova M, Frohlich J. The plasma parameter log (TG/HDL-C) as an atherogenic index: correlation with lipoprotein particle size and esterification rate in apoB-lipoprotein-depleted plasma (FER(HDL)). Clin Biochem. 2001; 34(7): 583–588.
 
15.
National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002; 106(25): 3143–3421.
 
16.
Matthews D R, Hosker J P, Rudenski A S, Naylor B A, Treacher D F, Turner R C: Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985; 28(7): 412–419.
 
17.
Hotta K, Funahashi T, Arita Y, Takahashi M, Matsuda M, Okamoto Y et al. Plasma concentrations of a novel, adipose-specific protein, adiponectin, in type 2 diabetic patients. Arterioscler Thromb Vasc Biol. 2000; 20(6): 1595–1599.
 
18.
Weyer C, Funahashi T, Tanaka S, Hotta K, Matsuzawa Y, Pratley RE, et al. Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemia. J Clin Endocrinol Metab. 2001; 86(5): 1930–1935.
 
19.
Catalano PM, Hoegh M, Minium J, Huston-Presley L, Bernard S, Kalhan S, et al. Adiponectin in human pregnancy: implications for regulation of glucose and lipid metabolism. Diabetologia 2006; 49(7): 1677–1685.
 
20.
Homko C, Sivan E, Chen X, Reece EA, Boden G. Insulin secretion during and after pregnancy in patients with gestational diabetes mellitus. J Clin Endocrinol Metab. 2001; 86(2): 568–573.
 
21.
McLachlan KA, O’Neal D, Jenkins A, Alford FP. Do adiponectin, TNFalpha, leptin and CRP relate to insulin resistance in pregnancy? Studies in women with and without gestational diabetes, during and after pregnancy. Diabetes Metab Res Rev. 2006; 22(2): 131–138.
 
22.
Liu T1, Fang Z, Yang D, Liu Q. Correlation between the inflammatory factors and adipocytokines with gestational diabetes mellitus and their change in puerperium. Zhonghua Fu Chan Ke Za Zhi. 2012; 47(6): 436–439.
 
23.
Cseh K, Baranyi E, Melczer Z, Kaszás E, Palik E, Winkler G. Plasma adiponectin and pregnancy-induced insulin resistance. Diabetes Care. 2004; 27(1): 274–275.
 
24.
Winzer C, Wagner O, Festa A, Schneider B, Roden M, Bancher-Todesca D, et al. Plasma adiponectin, insulin sensitivity, and subclinical inflammation in women with prior gestational diabetes mellitus. Diabetes Care. 2004; 27(7): 1721–1727.
 
25.
Kwon K, Jung SH, Choi C, Park SH. Reciprocal association between visceral obesity and adiponectin: in healthy premenopausal women. Int J Cardiol. 2005; 101(3): 385–390.
 
26.
Esposito K, Pontillo A, Di Palo C, Giugliano G, Masella M, Marfella R et al. Effect of weight loss and lifestyle changes on vascular inflammatory markers in obese women: a randomized trial. JAMA. 2003; 289(14): 1799–1804.
 
27.
Abbasi F, Lamendola C, McLaughlin T, Hayden J, Reaven GM, Reaven PD.Plasma adiponectin concentrations do not increase in association with moderate weight loss in insulin-resistant, obese women. Metabolism. 2004; 53(3): 280–283.
 
28.
Schaefer-Graf UM, Buchanan TA, Xiang AH, Peters RK, Kjos SL. Clinical predictors for a high risk for the development of diabetes mellitus in the early puerperium in women with recent gestational diabetes mellitus. Am J Obstet Gynecol. 2002; 186(4): 751–756.
 
29.
Spranger J, Kroke A, Möhlig M, Bergmann MM, Ristow M, Boeing H, et al. Adiponectin and protection against type 2 diabetes mellitus. Lancet. 2003; 361(9353): 226–228.
 
eISSN:1898-2263
ISSN:1232-1966